Balanced news tone
News Sentiment
ATRA sentiment intelligence
Atara Biotherapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
45
Balanced news tone
62 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-16.2% over one week, -6.2% over four weeks, trend inactive, and below fair value.
Enterprise value to EBITDA forward of Atara Biotherapeutics Inc – MUN:AT20
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
-16.2%
Price reacting lower
Trend fit
Trend inactive
-6.2% over four weeks
Fair value
-31.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
39
Negative
16
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Stock Titan
Direct company coverage
Atara Biotherapeutics (ATRA) director awarded 24,000 restricted stock units
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- Stock Titan
Business Wire
Direct company coverage
Atara Biotherapeutics Announces Changes to Its Board of Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Business Wire
Business Wire
Direct company coverage
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Business Wire
PR Newswire
Direct company coverage
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- PR Newswire
Los Angeles Business Journal
Direct company coverage
Atara Bounces Back with FDA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 07:00
- Source
- Los Angeles Business Journal
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Associated Press
Direct company coverage
Atara Biotherapeutics: Q1 Earnings Snapshot
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 May 2026 20:40
- Source
- Associated Press
Investing.com
Direct company coverage
EcoR1 Capital buys $4.74m in Atara Biotherapeutics stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Investing.com
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
Atara Biotherapeutics stock surges on FDA resubmission guidance
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 07 May 2026 07:00
- Source
- Investing.com
Market source
Direct company coverage
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
FDA says single-arm study could back Atara's tab-cel refiling
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- GlobeNewswire
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Business Wire
Direct company coverage
Stockholder Notice: Robbins LLP Informs Investors of the Atara Biotherapeutics, Inc. Class Action Lawsuit
- Tone
- Negative 34/100
- Event
- Regulatory and legal
- Published
- 23 Mar 2026 07:00
- Source
- Business Wire
Stock Titan
Direct company coverage
Atara presses FDA meeting on T-cell therapy for ultra-rare PTLD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Mar 2026 08:00
- Source
- Stock Titan
Business Wire
Direct company coverage
Atara Biotherapeutics Provides a Business Update
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Feb 2026 08:00
- Source
- Business Wire
simplywall.st
Direct company coverage
There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Feb 2026 08:00
- Source
- simplywall.st
Ventura County Star
Direct company coverage
Once a Ventura County biotech heavyweight, Atara fights for its life
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jan 2026 08:00
- Source
- Ventura County Star
Los Angeles Business Journal
Direct company coverage
FDA Again Rejects Atara
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jan 2026 08:00
- Source
- Los Angeles Business Journal
Investing.com
Direct company coverage
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- Investing.com
GuruFocus
Direct company coverage
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- GuruFocus
Business Wire
Direct company coverage
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 12 Jan 2026 08:00
- Source
- Business Wire
Reuters
Direct company coverage
US FDA declines to approve Atara's therapy for rare blood cancer
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 12 Jan 2026 08:00
- Source
- Reuters
Seeking Alpha
Direct company coverage
Atara Biotherapeutics: An Empty Pipeline With Little Gas (NASDAQ:ATRA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Nov 2025 08:00
- Source
- Seeking Alpha